MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$186,096K
Free Cash flow
-$97,807K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities and sales of marketab...
Stockbased compensation expense
Proceeds from exercise of awards...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Cash paid to acquire finite-live...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-127,553
-128,447
-128,549
-126,902
Depreciation and amortization
3,569
2,845
2,866
2,947
Stockbased compensation expense
22,915
23,087
23,951
25,135
Net accretion of discounts on marketable securities
1,445
1,259
1,642
2,026
Non-cash adjustment to operating lease expense
1,209
1,144
1,145
1,144
Right-of-use asset amortization for finance lease
915
916
916
915
Non-cash gain from divestiture of small molecule programs
-
-
0
0
Non-cash interest expense related to revenue participation right liability
5,941
-
-
-
Other non-cash items
517
-294
-49
-
Accounts receivable, net
3,927
-
-
-
Inventory
4,139
-
-
-
Prepaid expenses and other current assets
322
2,291
-1,747
-1,363
Other non-current assets
-396
700
533
1,717
Accounts payable
227
3,875
-3,408
-4,069
Accruals and other current liabilities
3,288
-22,395
12,727
1,889
Related party contract liability
-
-
0
-
Deferred research and development funding liability
4,859
-5,985
-5,517
-3,687
Other non-currentliabilities
-
-
0
-
Net cash used in operating activities
-97,002
-131,204
-98,538
-107,296
Purchases of marketable securities
271,505
123,074
252,708
50,629
Maturities and sales of marketable securities
197,032
220,000
275,000
107,081
Purchases of property and equipment
805
2,466
1,524
-1,378
Cash paid to acquire finite-lived intangible asset
28,800
-
-
-
Net cash provided by (used in) investing activities
-104,078
94,460
20,768
57,830
Proceeds from issuance / public offering of common stock and pre-funded warrants, net of issuance costs of-Private Placement
-
-
0
-
Proceeds from underwriter exercising option to purchase common stock, net of issuance costs
0
12,366
-
0
Proceeds from issuance / public offering of common stock and pre-funded warrants, net of issuance costs of-Public Offering
-
-
189,249
-
Proceeds from sale of revenue participation right
0
200,000
-
-
Proceeds from exercise of awards under equity incentive plans
15,005
6,695
3,224
583
Payments for finance lease right-of-use asset
21
17
16
1,361
Issuance costs related to the royalty financing
-
-
324
-
Net cash provided by (used in) financing activities
14,984
219,044
192,133
-778
Net decrease in cash, cash equivalents and restricted cash
-186,096
182,300
114,363
-50,244
Cash, cash equivalents and restricted cash at beginning of period
390,732
208,432
94,069
176,535
Cash, cash equivalents and restricted cash at end of period
204,636
390,732
208,432
94,069
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
awards under equity...
$15,005K
(222.55%↑ Y/Y)
Net cash provided by
(used in) financing...
$14,984K
(800.51%↑ Y/Y)
Canceled cashflow
$21K
Net decrease in
cash, cash...
-$186,096K
(-477.54%↓ Y/Y)
Canceled cashflow
$14,984K
Maturities and sales of
marketable securities
$197,032K
(-39.18%↓ Y/Y)
Stockbased compensation
expense
$22,915K
(-54.67%↓ Y/Y)
Non-cash interest
expense related to...
$5,941K
Deferred research and
development funding...
$4,859K
(-69.96%↓ Y/Y)
Depreciation and
amortization
$3,569K
(-33.54%↓ Y/Y)
Accruals and other
current liabilities
$3,288K
(123.24%↑ Y/Y)
Right-of-use asset
amortization for finance...
$915K
(-49.11%↓ Y/Y)
Other non-current
assets
-$396K
(86.90%↑ Y/Y)
Accounts payable
$227K
(627.91%↑ Y/Y)
Payments for finance
lease right-of-use...
$21K
(-99.69%↓ Y/Y)
Net cash provided by
(used in) investing...
-$104,078K
(-158.91%↓ Y/Y)
Net cash used in
operating activities
-$97,002K
(53.09%↑ Y/Y)
Canceled cashflow
$197,032K
Canceled cashflow
$42,110K
Purchases of marketable
securities
$271,505K
(96.85%↑ Y/Y)
Net loss
-$127,553K
(50.39%↑ Y/Y)
Cash paid to acquire
finite-lived intangible...
$28,800K
Purchases of property and
equipment
$805K
(-91.40%↓ Y/Y)
Inventory
$4,139K
Accounts receivable, net
$3,927K
Net accretion of
discounts on marketable...
$1,445K
(-78.06%↓ Y/Y)
Non-cash adjustment to
operating lease expense
$1,209K
(-44.05%↓ Y/Y)
Other non-cash items
$517K
Prepaid expenses and
other current assets
$322K
(-91.18%↓ Y/Y)
Buy us a coffee
Denali Therapeutics Inc. (DNLI)
Denali Therapeutics Inc. (DNLI)